Editor’s notice: Discover the newest COVID-19 information and steerage in Medscape’s Coronavirus Resource Center.
Oxford College is beginning a COVID-19 vaccine examine with kids and younger adults between ages 6 and 17.
At Oxford and three companion websites in London, Southampton, and Bristol, the section 2 medical trial will check whether or not children and youths have a superb immune response to the AstraZeneca vaccine. Earlier trials have proven that the shot is secure in kids.
“Whereas most youngsters are comparatively unaffected by coronavirus and are unlikely to turn out to be unwell with the an infection, you will need to set up the protection and immune response to the vaccine in kids and younger folks as some kids might profit from vaccination,” Andrew Pollard, PhD, the chief investigator for the trial and a professor of pediatric an infection and immunity at Oxford, stated in a press release.
The brand new trial will enroll 300 volunteers, with as much as 240 receiving the vaccine. The management group will obtain a meningitis vaccine, which is secure in kids and produces related unintended effects to the COVID-19 vaccine, reminiscent of a sore arm.
COVID-19 vaccine trials have included kids over age 12, so this marks the youngest group to be examined thus far. Pfizer, Moderna, and Janssen have introduced plans to begin trials in youthful kids this spring, in accordance with The Washington Put up. Widespread vaccination in kids probably will not happen till 2022, the newspaper reported.
The trial launched on Friday, and the primary vaccinations are anticipated by the top of the month. Dad and mom can go to Oxford’s COVID-19 Vaccine Trial web site to signal their kids up for the examine.
“This examine will play an essential position in serving to to guard kids sooner or later,” Grace Li, a pediatric medical analysis fellow for the Oxford Vaccine Group, stated within the assertion.
“We have already seen that the vaccine is secure and efficient in adults, and our understanding of how kids are affected by the coronavirus continues to evolve,” she stated.